Prophylactic bioCD19TM for Covid-19

Powered by Cube Labs

Logo-Design-Adamas-New

DTech and Adamas Biotech, both Cube Labs companies, have together developed prophylactic technology to combat Covid-19, soon to enter clinical trials.

bioCD19TM comprises a proprietary biogel-bioactive catechin mixture designed to be safely administered to the upper respiratory tract to prevent virus particles from infecting host cells. The components of the formulation have been tested for toxicity and safety.

Clinical studies will begin soon. For more information, Contact Us

Chiudi il menu